Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;2(1):A0021.
doi: 10.5702/massspectrometry.A0021. Epub 2013 Jun 1.

Quantification of Candesartan in Mouse Plasma by MALDI-TOFMS and in Tissue Sections by MALDI-Imaging Using the Stable-Isotope Dilution Technique

Affiliations

Quantification of Candesartan in Mouse Plasma by MALDI-TOFMS and in Tissue Sections by MALDI-Imaging Using the Stable-Isotope Dilution Technique

Toyofumi Nakanishi et al. Mass Spectrom (Tokyo). 2013.

Abstract

To determine the contents of candesartan in mouse plasma, and blood vessel and kidney sliced sections and also better understand its pharmacokinetics, we applied matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) and MALDI-imaging mass spectrometry (IMS) with the selected reaction monitoring (SRM) mode using a labeled-internal standard. The results of fundamental examinations showed that the slope of the resulting curves of candesartan in the plasma from the equation was 0.91 and the y-intercept was 0.02. Both intra- and inter-day accuracies (n=10) and the precision of candesartan in the plasma by MALDI-TOFMS with the SRM mode were in the range of 3.4 to 17.3% and 93.2%, respectively. The detection limit of candesartan in spiked plasma was 0.2 nmol/L. IMS analysis enabled us to clarify distinct spacial time-distribution images in sliced mouse blood vessel and kidney sections although it still needed to improve a protocol of quantification. Typical pharmacokinetic patterns of candesartan were obtained in the plasma and sliced kidney sections, but those in the blood vessel sections gradually increased 24 h after administration. MALDI-TOFMS and IMS with the SRM mode are powerful tools to identify the spacial distribution and traceability of candesartan in sliced blood vessel and tissue sections as well as in the plasma.

Keywords: MALDI-imaging; candesartan; pharmacokinetics; spacial localization; stable-isotope dilution technique.

PubMed Disclaimer

Figures

None
Fig. 1. MALDI post-source decay mass spectrum of CAD and CAD-d4 (CAD*) in the SRM mode. The monitor ions of CAD and CAD* were m/z 263.5 and m/z 267.5, respectively.
None
Fig. 2. Calibration curve of CAD contents between 5 nmol/L to 100 nmol/L. The calibration curve between 0.2 nmol/L to 2 nmol/L for the lower range is shown in the inset.
None
Fig. 3. Typical pharmacokinetic patterns in mouse plasma obtained after a single oral administration (30 mg/kg).
None
Fig. 4. Spacial time-distribution images in sliced mouse kidney (a) and blood vessel (b) sections by IMS with the SRM mode.
Each heat-map of the ion images at m/z 263.5 indicated the contents of CAD in sliced sections 0, 1, 6, and 24 h after the oral administration. Scanning images of each sliced section (upper) and heat-maps of ion images of CAD (lower) are shown. The data for sliced kidney was measured in single and those for blood vessel were in quadruplicate (mean±1 S.D.). #: pmol/mm2

Similar articles

Cited by

References

    1. 1) A. Joost, H. C. Schunkert, P. W. Radke. Candesartan cilexetil: An update. Expert Opin. Pharmacother. 12: 1769–1780, 2011 - PubMed
    1. 2) K. J. McClellan, K. L. Goa. Candesartan cilexetil: A review of its use in essential hypertension. Drugs 56: 847–869, 1998 - PubMed
    1. 3) I. Meineke, H. Feltkamp, A. Högemann, U. Gundert-Remy. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension: A population analysis. Eur. J. Clin. Pharmacol. 53: 221–228, 1997. - PubMed
    1. 4) A. Himmelmann, S. Keinänen-Kiukaanniemi, A. Wester, J. Redón, R. Asmar, T. Hedner; Effect Study Group. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press. 10: 43–51, 2001 - PubMed
    1. 5) H. Buter, G. Y. Navis, A. J. Woittiez, D. de Zeeuw, P. E. de Jong. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur. J. Clin. Pharmacol. 54: 953–958, 1999 - PubMed